Jinichi Mori1,2, Kumi Oshima1, Tetsuya Tanimoto3. Show Affiliations » 1. Jyoban Hospital of Tokiwakai Group, Iwaki, Japan 2. jin_ichi@hotmail.com 3. Navitas Clinic, Tokyo, Japan
Abstract
Entities: Chemical Disease
Mesh： See more » Antibodies, Bispecific/therapeutic useHumansPrecursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy
Substances： See more » Antibodies, Bispecificblinatumomab
Year: 2017 PMID： 28594155 DOI： 10.1056/NEJMc1704012
Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245